BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 10422789)

  • 41. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist.
    Shen CP; Xiao JC; Armstrong H; Hagmann W; Fong TM
    Eur J Pharmacol; 2006 Feb; 531(1-3):41-6. PubMed ID: 16438957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells.
    Jones JD; Carney ST; Vrana KE; Norford DC; Howlett AC
    Neuropharmacology; 2008 Jan; 54(1):23-30. PubMed ID: 17707868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor.
    Bosier B; Hermans E; Lambert D
    Br J Pharmacol; 2008 Sep; 155(1):24-33. PubMed ID: 18536748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor.
    Gouldson P; Calandra B; Legoux P; Kernéis A; Rinaldi-Carmona M; Barth F; Le Fur G; Ferrara P; Shire D
    Eur J Pharmacol; 2000 Jul; 401(1):17-25. PubMed ID: 10915832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor.
    Chin CN; Murphy JW; Huffman JW; Kendall DA
    J Pharmacol Exp Ther; 1999 Nov; 291(2):837-44. PubMed ID: 10525107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allosteric modulation of the cannabinoid CB1 receptor.
    Price MR; Baillie GL; Thomas A; Stevenson LA; Easson M; Goodwin R; McLean A; McIntosh L; Goodwin G; Walker G; Westwood P; Marrs J; Thomson F; Cowley P; Christopoulos A; Pertwee RG; Ross RA
    Mol Pharmacol; 2005 Nov; 68(5):1484-95. PubMed ID: 16113085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
    Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
    Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.
    Bouaboula M; Desnoyer N; Carayon P; Combes T; Casellas P
    Mol Pharmacol; 1999 Mar; 55(3):473-80. PubMed ID: 10051530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation.
    Carayon P; Marchand J; Dussossoy D; Derocq JM; Jbilo O; Bord A; Bouaboula M; Galiègue S; Mondière P; Pénarier G; Fur GL; Defrance T; Casellas P
    Blood; 1998 Nov; 92(10):3605-15. PubMed ID: 9808554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures.
    Molina-Holgado F; Molina-Holgado E; Guaza C; Rothwell NJ
    J Neurosci Res; 2002 Mar; 67(6):829-36. PubMed ID: 11891798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacology of cannabinoid CB1 and CB2 receptors.
    Pertwee RG
    Pharmacol Ther; 1997; 74(2):129-80. PubMed ID: 9336020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling.
    Shore DM; Baillie GL; Hurst DH; Navas F; Seltzman HH; Marcu JP; Abood ME; Ross RA; Reggio PH
    J Biol Chem; 2014 Feb; 289(9):5828-45. PubMed ID: 24366865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.
    Bayewitch M; Rhee MH; Avidor-Reiss T; Breuer A; Mechoulam R; Vogel Z
    J Biol Chem; 1996 Apr; 271(17):9902-5. PubMed ID: 8626625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.
    Shire D; Calandra B; Delpech M; Dumont X; Kaghad M; Le Fur G; Caput D; Ferrara P
    J Biol Chem; 1996 Mar; 271(12):6941-6. PubMed ID: 8636122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors.
    Lambert DM; DiPaolo FG; Sonveaux P; Kanyonyo M; Govaerts SJ; Hermans E; Bueb J; Delzenne NM; Tschirhart EJ
    Biochim Biophys Acta; 1999 Sep; 1440(2-3):266-74. PubMed ID: 10521710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subversion and utilization of the host cell cyclic adenosine 5'-monophosphate/protein kinase A pathway by Brucella during macrophage infection.
    Gross A; Bouaboula M; Casellas P; Liautard JP; Dornand J
    J Immunol; 2003 Jun; 170(11):5607-14. PubMed ID: 12759440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis.
    Gross A; Terraza A; Marchant J; Bouaboula M; Ouahrani-Bettache S; Liautard JP; Casellas P; Dornand J
    J Leukoc Biol; 2000 Mar; 67(3):335-44. PubMed ID: 10733093
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling.
    Bayewitch M; Avidor-Reiss T; Levy R; Barg J; Mechoulam R; Vogel Z
    FEBS Lett; 1995 Nov; 375(1-2):143-7. PubMed ID: 7498464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.
    Shire D; Calandra B; Bouaboula M; Barth F; Rinaldi-Carmona M; Casellas P; Ferrara P
    Life Sci; 1999; 65(6-7):627-35. PubMed ID: 10462063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
    Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
    J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.